Antiviral Activities of Two Nucleos(t)ide Analogs Against Vaccinia and Mpox Viruses in Primary Human Fibroblasts

Overview

Journal bioRxiv

Date 2023 Mar 30

PMID 36993701

Authors

Lara Dsouza

Anil Pant

Samuel Offei

Lalita Priyamvada

Blake Pope

Panayampalli S Satheshkumar

Zhengqiang Wang

Zhilong Yang

Affiliations

Soon will be listed here.

Abstract

Many poxviruses are significant human and animal pathogens, including viruses that cause smallpox and mpox. Identification of inhibitors of poxvirus replication is critical for drug development to manage poxvirus threats. Here we tested two compounds, nucleoside trifluridine and nucleotide adefovir dipivoxil, for antiviral activities against vaccinia virus (VACV) and mpox virus (MPXV) in physiologically relevant primary human fibroblasts. Both trifluridine and adefovir dipivoxil potently inhibited replication of VACV and MPXV (MA001 2022 isolate) in a plaque assay. Upon further characterization, they both conferred high potency in inhibiting VACV replication with half maximal effective concentrations (EC ) at low nanomolar levels in our recently developed assay based on a recombinant VACV secreted Gaussia luciferase. Our results further validated that the recombinant VACV with Gaussia luciferase secretion is a highly reliable, rapid, non-disruptive, and simple reporter tool for identification and chracterization of poxvirus inhibitors. Both compounds inhibited VACV DNA replication and downstream viral gene expression. Given that both compounds are FDA-approved drugs, and trifluridine is used to treat ocular vaccinia in medical practice due to its antiviral activity, our results suggest that it holds great promise to further test trifluridine and adefovir dipivoxil for countering poxvirus infection, including mpox.

References

Peng C, Zhou Y, Cao S, Pant A, Campos Guerrero M, McDonald P . Identification of Vaccinia Virus Inhibitors and Cellular Functions Necessary for Efficient Viral Replication by Screening Bioactives and FDA-Approved Drugs. Vaccines (Basel). 2020; 8(3). PMC: 7564539. DOI: 10.3390/vaccines8030401. View

Tannous B, Teng J . Secreted blood reporters: insights and applications. Biotechnol Adv. 2011; 29(6):997-1003. PMC: 3189544. DOI: 10.1016/j.biotechadv.2011.08.021. View

Carvalho T . The unknown efficacy of tecovirimat against monkeypox. Nat Med. 2022; 28(11):2224-2225. DOI: 10.1038/d41591-022-00094-0. View

Chou S, Marousek G, Guentzel S, Follansbee S, Poscher M, Lalezari J . Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis. 1997; 176(3):786-9. DOI: 10.1086/517302. View

Lyseng-Williamson K, Reynolds N, Plosker G . Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005; 65(3):413-32. DOI: 10.2165/00003495-200565030-00006. View

De Clercq E, Holy A . Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov. 2005; 4(11):928-40. DOI: 10.1038/nrd1877. View

Altmann S, Brandt C, Murphy C, Patnaikuni R, Takla T, Toomey M . Evaluation of therapeutic interventions for vaccinia virus keratitis. J Infect Dis. 2011; 203(5):683-90. PMC: 3072718. DOI: 10.1093/infdis/jiq103. View

Yang Z, Gray M, Winter L . Why do poxviruses still matter?. Cell Biosci. 2021; 11(1):96. PMC: 8140567. DOI: 10.1186/s13578-021-00610-8. View

Chan-Tack K, Harrington P, Bensman T, Choi S, Donaldson E, ORear J . Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation. Antiviral Res. 2021; 195:105182. DOI: 10.1016/j.antiviral.2021.105182. View

10.

Lea A, Bryson H . Cidofovir. Drugs. 1996; 52(2):225-230; discussion 231. DOI: 10.2165/00003495-199652020-00006. View

11.

Yang Z, Reynolds S, Martens C, Bruno D, Porcella S, Moss B . Expression profiling of the intermediate and late stages of poxvirus replication. J Virol. 2011; 85(19):9899-908. PMC: 3196450. DOI: 10.1128/JVI.05446-11. View

12.

Cotter C, Earl P, Wyatt L, Moss B . Preparation of Cell Cultures and Vaccinia Virus Stocks. Curr Protoc Protein Sci. 2017; 89:5.12.1-5.12.18. DOI: 10.1002/cpps.34. View

13.

Grosenbach D, Honeychurch K, Rose E, Chinsangaram J, Frimm A, Maiti B . Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018; 379(1):44-53. PMC: 6086581. DOI: 10.1056/NEJMoa1705688. View

14.

Yang Z, Bruno D, Martens C, Porcella S, Moss B . Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing. Proc Natl Acad Sci U S A. 2010; 107(25):11513-8. PMC: 2895082. DOI: 10.1073/pnas.1006594107. View

15.

Parkhurst J, Danenberg P, HEIDELBERGER C . Growth inhibition of cells in cultures and of vaccinia virus infected HeLa cells by derivatives of trifluorothymidine. Chemotherapy. 1976; 22(3-4):221-31. DOI: 10.1159/000221929. View

16.

Carmine A, Brogden R, Heel R, Speight T, Avery G . Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs. 1982; 23(5):329-53. DOI: 10.2165/00003495-198223050-00001. View

17.

Pant A, Cao S, Yang Z . Asparagine Is a Critical Limiting Metabolite for Vaccinia Virus Protein Synthesis during Glutamine Deprivation. J Virol. 2019; 93(13). PMC: 6580962. DOI: 10.1128/JVI.01834-18. View

18.

De Clercq E, Li G . Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016; 29(3):695-747. PMC: 4978613. DOI: 10.1128/CMR.00102-15. View

19.

Erice A, Perez J, Balfour Jr H, Sannerud K, Hanson M, Boivin G . Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis. 1997; 175(5):1087-92. DOI: 10.1086/516446. View

20.

Yu B, Chang J . The first Chinese oral anti-COVID-19 drug Azvudine launched. Innovation (Camb). 2022; 3(6):100321. PMC: 9461232. DOI: 10.1016/j.xinn.2022.100321. View